Management of Hypertensive Urgency with CHF and Atrial Fibrillation

Immediate Assessment and Stabilization

The American Heart Association recommends assessing whether the patient has decompensated heart failure, as this fundamentally changes the medication approach 1, 2
Evaluate ejection fraction if known, though in the acute setting this may not alter initial management, according to the American College of Cardiology 1, 3
Check for hemodynamic instability—if present, proceed directly to electrical cardioversion, as recommended by the European Society of Cardiology 4, 2

For decompensated CHF with AF and RVR, the American Heart Association recommends IV digoxin as the preferred first-line agent (Class I, Level B recommendation) 1, 2
IV amiodarone is equally appropriate when other measures are unsuccessful or contraindicated (Class IIa, Level C), according to the American College of Cardiology 1, 2
Beta-blockers should be used with extreme caution in patients with overt congestion, hypotension, or decompensated HFrEF—this is a Class III: Harm recommendation, as stated by the American Heart Association 1, 2

Address volume overload with IV furosemide as the initial step, according to the American College of Cardiology 6
Uptitrate beta-blocker (carvedilol) to target dose (25 mg twice daily or metoprolol equivalent 100-200 mg daily) as tolerated, monitoring for hypotension and decompensation, as recommended by the European Society of Cardiology 3
Target resting heart rate <100 bpm and <110 bpm during moderate exercise, according to the European Heart Journal 5, 3

Determine if patient is decompensated—if yes, use IV digoxin or IV amiodarone; if no, beta-blockers are acceptable, as recommended by the American Heart Association 1, 2
Target lenient rate control initially (resting HR <110 bpm) unless symptoms require stricter control, according to the European Heart Journal 5, 2

Assess stroke risk using CHA₂DS₂-VASc score and initiate oral anticoagulation for all patients except those at low risk (score 0 in males, 1 in females), as recommended by the European Society of Cardiology 5, 4
Direct oral anticoagulants (DOACs) are preferred over warfarin in eligible patients, according to the European Heart Journal 4
Continue anticoagulation regardless of whether rate or rhythm control is achieved if thromboembolic risk factors are present, as stated by the European Society of Cardiology 4

AV node ablation with ventricular pacing is reasonable when pharmacological therapy is insufficient or not tolerated, according to the American College of Cardiology 1, 2
AV node ablation should NOT be performed without a prior pharmacological trial to achieve ventricular rate control (Class III: Harm), as recommended by the American Heart Association 1, 2